ReviewLung2026

Phase 3 Antifibrotic-Directed Therapy Outcomes in Idiopathic Pulmonary Fibrosis: Beyond FVC Decline.

Fumihiro Kashizaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.